Cargando…
Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study
OBJECTIVE: To assess if different forms of regulation lead to differences in the quality of journal advertisements. DESIGN: Cross-sectional study. PARTICIPANTS: Thirty advertisements from family practice journals published from 2013 to 2015 were extracted for three countries with distinct regulatory...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371147/ https://www.ncbi.nlm.nih.gov/pubmed/32690502 http://dx.doi.org/10.1136/bmjopen-2019-034993 |
_version_ | 1783561089254948864 |
---|---|
author | Diep, Dion Mosleh-Shirazi, Abnoos Lexchin, Joel |
author_facet | Diep, Dion Mosleh-Shirazi, Abnoos Lexchin, Joel |
author_sort | Diep, Dion |
collection | PubMed |
description | OBJECTIVE: To assess if different forms of regulation lead to differences in the quality of journal advertisements. DESIGN: Cross-sectional study. PARTICIPANTS: Thirty advertisements from family practice journals published from 2013 to 2015 were extracted for three countries with distinct regulatory pharmaceutical promotion systems: Australia, Canada and the USA. PRIMARY AND SECONDARY OUTCOME MEASURES: Advertisements under each regulatory system were compared concerning three domains: information included in the advertisement, references to scientific evidence and pictorial appeals and portrayals. An overall ranking for advertisement quality among countries was determined using the first two domains as the information assessed has been associated with more appropriate prescribing. RESULTS: Advertisements varied significantly for number of claims with quantitative benefit (Australia: 0.0 (0.0–3.0); Canada: 0.0 (0.0–5.0); USA: 1.0 (0.0–6.0); p=0.01); statistical method used in reporting benefit (relative risk reduction, absolute risk reduction and number needed to treat; Australia: 6.7%, n=2; Canada: 10.0%, n=3; USA: 36.6%, n=11; p=0.02); mention of adverse effects, warnings or contraindications (Australia: 13.3%, n=4; Canada: 23.3%, n=7; USA: 53.3%, n=16; p=0.002); equal prominence between safety and benefit information (Australia: 25.0%, n=1; Canada: 28.6%, n=2; USA: 75.0%, n=12; p=0.04); and methodological quality of references score (Australia: 0.4150 (0.25–0.70); Canada: 0.25 (0.00–0.63); USA: 0.25 (0.00–0.75); p<0.001). The USA ranked first, Canada second and Australia third for overall quality of journal advertisements. Significant differences for humour appeals (Australia: 3.3%, n=1; Canada: 13.3%, n=4; USA: 26.7%, n=8; p=0.04), positive emotional appeals (Australia: 26.7%, n=8; Canada: 60.0%, n=18; USA: 50.0%, n=15; p=0.03), social approval portrayals (Australia: 0.0%, n=0; Canada: 0.0%, n=0; USA: 10.0%, n=3; p=0.04) and lifestyle or work portrayals (Australia: 43.3%, n=13; Canada: 50.0%, n=15; USA: 76.7%, n=23; p=0.02) were found among countries. CONCLUSIONS: Different regulatory systems influence journal advertisement quality concerning all measured domains. However, differences may also be attributed to other regulatory, legal, cultural or health system factors unique to each country. |
format | Online Article Text |
id | pubmed-7371147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-73711472020-07-22 Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study Diep, Dion Mosleh-Shirazi, Abnoos Lexchin, Joel BMJ Open Health Policy OBJECTIVE: To assess if different forms of regulation lead to differences in the quality of journal advertisements. DESIGN: Cross-sectional study. PARTICIPANTS: Thirty advertisements from family practice journals published from 2013 to 2015 were extracted for three countries with distinct regulatory pharmaceutical promotion systems: Australia, Canada and the USA. PRIMARY AND SECONDARY OUTCOME MEASURES: Advertisements under each regulatory system were compared concerning three domains: information included in the advertisement, references to scientific evidence and pictorial appeals and portrayals. An overall ranking for advertisement quality among countries was determined using the first two domains as the information assessed has been associated with more appropriate prescribing. RESULTS: Advertisements varied significantly for number of claims with quantitative benefit (Australia: 0.0 (0.0–3.0); Canada: 0.0 (0.0–5.0); USA: 1.0 (0.0–6.0); p=0.01); statistical method used in reporting benefit (relative risk reduction, absolute risk reduction and number needed to treat; Australia: 6.7%, n=2; Canada: 10.0%, n=3; USA: 36.6%, n=11; p=0.02); mention of adverse effects, warnings or contraindications (Australia: 13.3%, n=4; Canada: 23.3%, n=7; USA: 53.3%, n=16; p=0.002); equal prominence between safety and benefit information (Australia: 25.0%, n=1; Canada: 28.6%, n=2; USA: 75.0%, n=12; p=0.04); and methodological quality of references score (Australia: 0.4150 (0.25–0.70); Canada: 0.25 (0.00–0.63); USA: 0.25 (0.00–0.75); p<0.001). The USA ranked first, Canada second and Australia third for overall quality of journal advertisements. Significant differences for humour appeals (Australia: 3.3%, n=1; Canada: 13.3%, n=4; USA: 26.7%, n=8; p=0.04), positive emotional appeals (Australia: 26.7%, n=8; Canada: 60.0%, n=18; USA: 50.0%, n=15; p=0.03), social approval portrayals (Australia: 0.0%, n=0; Canada: 0.0%, n=0; USA: 10.0%, n=3; p=0.04) and lifestyle or work portrayals (Australia: 43.3%, n=13; Canada: 50.0%, n=15; USA: 76.7%, n=23; p=0.02) were found among countries. CONCLUSIONS: Different regulatory systems influence journal advertisement quality concerning all measured domains. However, differences may also be attributed to other regulatory, legal, cultural or health system factors unique to each country. BMJ Publishing Group 2020-07-19 /pmc/articles/PMC7371147/ /pubmed/32690502 http://dx.doi.org/10.1136/bmjopen-2019-034993 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Health Policy Diep, Dion Mosleh-Shirazi, Abnoos Lexchin, Joel Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study |
title | Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study |
title_full | Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study |
title_fullStr | Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study |
title_full_unstemmed | Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study |
title_short | Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study |
title_sort | quality of advertisements for prescription drugs in family practice medical journals published in australia, canada and the usa with different regulatory controls: a cross-sectional study |
topic | Health Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371147/ https://www.ncbi.nlm.nih.gov/pubmed/32690502 http://dx.doi.org/10.1136/bmjopen-2019-034993 |
work_keys_str_mv | AT diepdion qualityofadvertisementsforprescriptiondrugsinfamilypracticemedicaljournalspublishedinaustraliacanadaandtheusawithdifferentregulatorycontrolsacrosssectionalstudy AT moslehshiraziabnoos qualityofadvertisementsforprescriptiondrugsinfamilypracticemedicaljournalspublishedinaustraliacanadaandtheusawithdifferentregulatorycontrolsacrosssectionalstudy AT lexchinjoel qualityofadvertisementsforprescriptiondrugsinfamilypracticemedicaljournalspublishedinaustraliacanadaandtheusawithdifferentregulatorycontrolsacrosssectionalstudy |